The authors found that OX40L expression in Ewing sarcoma cells enhanced immune stimulation, suggesting that the OX40/OX40L pathways should be considered in the design of immunotherapies against Ewing sarcoma (Reuter et al.). Here, TNFRSF4 is linked to Ewing sarcoma.